Nyxoah stock drops further

A decline of more than 5% that pushes the stock below its two first moving averages

Nyxoah falls 5.53% to €1.33 during the session, while the CAC 40 rises 0.21% and the SBF 120 advances by a similar magnitude. This decline places the stock slightly below the 20-day moving average (€1.34) and the 50-day moving average (€1.34), two averages that converge at the same level and now form a near-term resistance. The 200-day moving average, at €2.53, remains nearly 47% above the current price, highlighting the extent of the downward movement over the long term.

Over the quarter, the stock falls 13.33%, while the decline reaches 65.56% over one year, placing Nyxoah in an unfavorable underlying trend despite a slight rebound of 1.84% over the past seven days. The RSI at 55 remains in neutral territory, with no oversold signal despite the amplitude of today's movement, which does not indicate immediate selling exhaustion in the short term.

The ACCCESS study as a fundamental anchor point, between clinical results and commercial trajectory

Fundamentally, Nyxoah announced on September 2, 2026 that its pivotal American ACCCESS study had achieved its primary efficacy and safety co-endpoints in patients suffering from complete concentric collapse of the soft palate. This announcement, which concerned a prospective multicenter study with three-year follow-up, represents a significant regulatory milestone for the Belgian company's neurostimulation device. Furthermore, first-half 2026 revenue had reached €14 million, with stable operating loss, following a 21% increase in the second quarter.

Cash reserves stood at €97.8 million at the end of June, according to data released in July. The technical support level at €1.14 remains the reference to monitor should the decline accelerate in upcoming sessions.